Simon Devos

This study investigates combining dexamethasone with PPAR agonist GW7647 to improve glucocorticoid efficacy and reduce metabolic side effects in rheumatoid arthritis models.

The paper uses proteomics to show increased ECM remodeling and complement activation in cardiac ATTR amyloidosis.

This paper introduces a high-throughput and ultrasensitive immunopeptidomics platform that identifies thousands of MHC I and II peptides from low-input samples.

ProteoBench provides a centralized platform for comparing proteomics data analysis workflows, enabling benchmarking and community collaboration.

CAMPI-2 evaluates five fecal sample stabilization methods for metaproteomics, finding one commercial device offers the best reproducibility and stability during room-temperature storage.

The paper compares DIA and DDA methods for immunopeptidomics, showing DIA improves detection of low-abundant bacterial epitopes from Listeria monocytogenes.

This paper introduces FibeRtypeR, a tool to estimate muscle fiber type proportions from bulk transcriptomics and proteomics data using single-fiber reference profiles.

This study maps the proximity interactome of NR2E3 and its G56R variant using TurboID, revealing interactions with retinal development complexes and identifying BCOR as enriched in the mutant network.

This study harmonizes quality controls across proteomics core facilities to improve data comparability and reliability through a 4-year longitudinal dataset and common processing software.

The paper introduces a dual-column electrospray source for nano-flow proteomics to improve throughput while maintaining sensitivity in low-input samples.

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

This study benchmarks 12 DIA analysis workflows for shotgun proteomics samples, finding DIA-NN and Spectronaut in library-free mode offer highest sensitivity with good reproducibility and accuracy.

This study identifies optimal sites for introducing N-glycans on VHH antibodies to enhance macrophage delivery, demonstrating glycan-dependent uptake in vitro and in vivo.

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.

The paper identifies off-target glycans formed during the engineering of Pichia pastoris to produce humanized N-glycans, highlighting challenges in achieving precise glycosylation control.